MedTrace Logo

Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients

NCT01363271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7260

Last updated 2012-05-22

No results posted yet for this study

Summary

This is a retrospective, observational, non-interventional drug study using de-identified data from two administrative claims datasets. The study design and analysis will reflect the perspective of the commercially insured. The objectives of this study are twofold:

1. To compare the rates of re-hospitalization among patients treated with either linezolid orally or IV, or vancomycin IV for complicated skin and skin structure infections (cSSSI) or pneumonia hospitalization.
2. To compare the total direct medical costs of patients treated with linezolid orally or IV, or vancomycin IV for cSSSI or pneumonia hospitalization.

Conditions

  • Complicated Skin and Structure Infection
  • Nosocomial Pneumonia

Interventions

DRUG

Linezolid

IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).

DRUG

Vancomycin

IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).

DRUG

Linezolid

IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).

DRUG

Vancomycin

IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).

Sponsors & Collaborators

  • University of Maryland

    collaborator OTHER

  • Lodise & Lodise, LLC

    collaborator UNKNOWN

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01363271 on ClinicalTrials.gov